An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

Also called NCT03510884

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 153 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03510884
  • EudraCT 2017-001903-60
Other papers using this trial's data
  • Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial JAMA pediatrics, 2024-03-01 DOI, PubMed 38315470, PMC10845038 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Hungary, Italy, Lebanon, Mexico, Netherlands, Norway, Poland, Russia, Slovenia, South Africa, Spain, Sweden, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03510884. Randomized; triple masking; primary purpose treatment. Start 2018-05-31 (actual); primary completion 2021-01-14 (actual). Results posted on 2023-05-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Condition
Hypercholesterolaemia
Intervention (Drug)
Alirocumab SAR236553 (REGN727)
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Simvastatin
Intervention (Drug)
Pravastatin
Intervention (Drug)
Lovastatin
Intervention (Drug)
Fluvastatin
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Cholestyramine
Intervention (Drug)
Nicotinic acid
Intervention (Drug)
Fenofibrate
Intervention (Drug)
Omega-3 fatty acids
Intervention (Drug)
Placebo
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03510884
Content hash
7459a246dc9d64c7195b765415cfcc93b68b60b3c11f6b68115716e76b447e76